Atypical PKC: A target for treating insulin-resistant disorders of obesity, the metabolic syndrome and type 2 diabetes mellitus

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 10, 2014, Pages 1163-1175

  Farese, Robert V ^a,b   Lee, MacKenzie C ^a,b   Sajan, Mini P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Diabetes; Insulin resistance; Obesity; PKC zeta lambda

Indexed keywords

CHEMICAL AGENT; INSULIN; LIPID; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PKC-3 PROTEIN;

DIABETIC PATIENT; DRUG SAFETY; DRUG TARGETING; EXERCISE; FATTY LIVER; GENE DELETION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID HOMEOSTASIS; LIVER CELL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; OBESITY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUG DESIGN; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICE; MOLECULAR TARGETED THERAPY; OBESITY; PROTEIN KINASE C;

EID: 84907059795     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.944897     Document Type: Review

References (33)

1. Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-69
2. Farese RV, Sajan MP, Wang H, et al. Muscle-specific knockout of PKClambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 2007;117:2289-301
3. Sajan MP, Nimal S, Mastorides S, et al. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome and type 2 diabetes by inhibitors of hepatic protein kinase C-iota. Metab 2012;61:459-69
4. Sajan MP, Ivy RA III, Lee MA, et al. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/Propeller/FYVE scaffold and is selectively inhibited by atypical PKC in early phases of diet-induced obesity: A mechanism for impairing gluconeogenic but not lipogenic enzyme expression. Diabetes 2014. [Epub ahead of print] .
5. Yang G, Badeaulou L, Bielawski J, et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009;297:E211-24
6. Ussher JR, Koves TR, Cadete VJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010;59:2453-64
7. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011;121:4222-30
8. Beeson M, Sajan MP, Dizon M, et al. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance:amelioration by rosiglitazone and exercise. Diabetes 2003;52:1926-34 .
9. Temofonte N, Sajan MP, Nimal S, et al. Combined thialidinedione-metformin treatment synergistically improves insulin signaling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinasse, atypical protein kinase C and protein kinase B/akt in human muscle. Diabetologia 2009;52:60-4
10. Cusi K, Consoli A, DeFronzo R. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes. J Clin Endocrinol Metab 1996;81:4059-67
11. Luna V, Casauban L, Sajan MP, et al. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4) in diabetic muscle. Diabetologia 2006;49:375-82
12. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
13. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-81
14. Stephenne X, Foretz M, Talcux N, et al. Metformin activates AMP-activated kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011;54:3101-10
15. Sajan MP, Ivy RA III, Farese RV. Meformin action in human hepatocytes: Coactivation of atypical protein kinase C alters 5'-AMP-activated protein kinase effects on lipogenic and gluconeogenic enzyme expression. Diabetologia 2013;56:2507-16
16. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009;15:635-46
17. Standaert ML, Sajan MP, Miura A, et al. Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high-fat-induced insulin-resistant states. J Biol Chem. 2004;279:24929-34
18. Sajan MP, Standaert ML, Nimal S, et al. Critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity. J Lipid Res 2009;50:1133-45 .
19. Sajan MP, Farese RV. Insulin signalling in hepatocytes of type 2 diabetic humans. excessive expression and activity of PKCiota and dependent processes and reversal by PKC-iota inhibitors. Diabetologia 2012;55:1446-57 .
20. Farese RV, Sajan MP. Metabolic functions of atypical protein kinase C: "Good and Bad" as defined by nutritional status (invited review) Am J Physiol Endocrinol Metab 2010;298:E385-94
21. Guo S, Copps KD, Park S, et al. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 2009;29:5070-83
22. Sajan MP, Standaert ML, Rivas J, et al. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as model of diabetes, and relationships to hyperlipidaemia and insulin resistance. Diabetologia 2009;52:1197-207
23. Kitamura Y, Accilli D. New insights into the integrated physiology of insulin action. Rev Endocr Metab Disord 2004;5:143-9
24. Matsumoto M, Pocal A, Rossetti L, et al. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. Cell Metab 2007;6:208-16
25. Matsumoto M, Ogawa W, Akimoto K, et al. PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 2003;112:935-44
26. Taniguchi CM, Kondo T, Sajan MP, et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta/. Cell Metab 2006;3:343-53
27. Fleischmann M, Iynedjian PB. Regulation of sterol regulatory element binding protein 1 gene expression in liver: Role of insulin and protein kinase B/cAkt. Biochem J 2000;349:13-17
28. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: MTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010;107:3441-6
29. Cai DM, Yuan DF, Frantz PA, et al. Local and systemic insulin resistance resulting from hepatic activation of IKKbeta and NF-kappaB. Nat Med 2005;11:183-90
30. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation and insulin resistance. Gastroenterology 2007;132:2169-80
31. Kim Y-B, Kotani K, Ciaraldi TP, et al. Insulin-stimulated protein kinase Clambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes; reversal with weight reduction. Diabetes 2003;52:1935-42
32. Beeson M, Sajan MP, Gomez-Daspet J, et al. Defective activation of protein kinase C-zeta in muscle by insulin and phosphatidylinositol-3,4,5-(PO4)3 in obesity and polycystic ovary syndrome. Metab Syndr Relat Disord 2004;2:49-56
33. Sajan MP, Ivey RA III, Lee M, et al. PKC lambda happloinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes. Mol Endocrinol 2014;28(7):1097-107